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Food allergy is a major health concern in industrialized
countries, affecting approximately 3.9% of children.
Peanut allergy is one of the most common forms of
food allergy, with approximately 3 million Americans
reporting allergy to peanuts or tree nuts, and the pre-
valence appears to be increasing. Peanut and tree nut
allergy account for the vast majority of life-threatening
or fatal allergic reactions to foods. In addition, peanut
allergy is often life-long, with only 20% of children out-
growing their allergy. Current treatment options are
limited to strict peanut avoidance and ready access to
epinephrine. Challenges for patients and families with
food allergy are considerable, and accidental ingestion
is common. Anxiety impairs social functioning and
quality of life in food-allergic individuals, who report
poorer health-related quality of life than those with
diabetes mellitus. These findings underscore the need
for active treatment strategies. Animal and human stu-
dies have examined potential therapies for peanut
allergy, including allergen-nonspecific and allergen-spe-
cific modalities; however, recent meta-analyses high-
light the shortage of controlled studies in the field.
TNX-901, a humanized monoclonal antibody that
binds IgE and prevents its binding to the high-affinity
IgE receptor on mast cells and basophils, was found to
increase the threshold of peanut protein inducing
symptoms in peanut-allergic individuals from less than
one peanut (178 mg) to almost twelve peanuts (2805
mg). However, this effect was seen only at the highest
dose tested, and the prohibitive cost of monoclonal
antibody treatment may limit this approach. A combi-
nation of traditional Chinese herbal medications, food
allergy herbal formula 2 (FAHF-2), has shown promise
in eliminating anaphylaxis to peanut in murine and
phase I studies. Allergen immunotherapy, an allergen-
specific treatment, refers to the administration of
increasing amounts of an allergen to individuals with
IgE-mediated allergy in order to induce immunologic
changes which diminish the allergic response to the
substance on subsequent encounters. Traditional sub-
cutaneous immunotherapy with aqueous peanut extract
was attempted but had an unacceptably high rate of
systemic reactions, despite favorable challenge
outcomes.
In pilot studies, our group has shown that open-label
peanut oral immunotherapy (OIT) was relatively safe
when performed in a supervised medical setting by
trained personnel and was associated with clinical
desensitization for the majority of subjects who com-
pleted more than eight months of treatment. We use
the term desensitization to signify a change in threshold
of ingested food antigen needed to cause allergic symp-
toms; this state is dependent on regular exposure to the
allergen. In contrast, tolerance refers to the induction of
long-term immunologic changes associated with the
ability to ingest a food without symptoms and without
ongoing therapy.
In order to establish the safety and efficacy of peanut
OIT as an allergen-specific therapy for peanut allergy,
we conducted the first randomized, double-blind, pla-
cebo-controlled study of OIT in children with peanut
allergy. Our goals were to evaluate the ability of peanut
OIT to safely raise the threshold of ingested food anti-
g e nw h e nc o m p a r e dw i t hp l a c e b oa n dt op e r f o r m
immunologic studies to investigate the underlying
mechanisms associated with clinical efficacy. The pri-
mary endpoint was to determine if, after one year of
treatment, subjects receiving peanut OIT would be able
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